British Biotech Pharmaceuticals Limited

British Bio-technology Limited

Christopher Norman Lewis

Fionna Mitchell Martin

Christopher David Floyd

Mark Whittaker

Alan H Davidson

Stephen Arthur Bowles

Richard S Todd

Jonathan P Dickens

Richard Simon Todd

Christopher D Floyd

Alan H Drummond

Metalloproteinase inhibitors

The present invention describes processes for preparing desired synthetic products that comprise a covalently bonded hydroxamic acid group &mdash;CONHOH by forming a mixture of a liquid reaction medium and a solid phase reaction product that carries a plurality of moieties of formula (A1) or (B1):

Synthesis of hydroxamic acid derivatives

The present invention describes solid phase reaction products of a solid substrate carrying a plurality of covalently bound hydroxylamine or protected hydroxylamine groups of formula (A) or (B): ##STR1## where P.sub.1 is hydrogen or an amino protecting group, P.sub.2 is hydrogen or a hydroxyl protecting group, and the bond designated (a) covalently links the formula (A) or (B) to the residue of the solid substrate, and is cleavable under acid conditions or by photolysis. The solid phase reaction products can be used for the synthesis of hydroxamic acid derivatives or a combinatorial library of such compounds.

Preparation of allyl succinate derivatives and starting materials

6-(hydronaphtyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones

Compounds of either of general formulae I and II: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, a, b, c, and d are variables. These compounds are useful in the treatment of hypercholesterolaemia in general and arteriosclerosis, familial hypercholesterolaemia or hyperlipidaemia in particular.

Decaline based HMC-COA reductase inhibitors with two C-6 substituents

Growing community of inventors

Oxford, United Kingdom

Christopher Norman Lewis